Kamsagara Linganna Krishna

Dr. Kamsagara Linganna Krishna


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
AJAvijeet Jain
Avijeet Jain
MSManish Soni
Manish Soni
LDLokesh Deb
Lokesh Deb
AJAnurekha Jain
Anurekha Jain
SRS.P. Rout
S.P. Rout
KKKamsagara Linganna Krishna
Kamsagara Linganna Krishna

1 November 2023 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
SMSeema Mehdi
Seema Mehdi
SWShahid Ud Din Wani
Shahid Ud Din Wani
KKKamsagara Linganna Krishna
Kamsagara Linganna Krishna
Nabeel KinattingalNabeel Kinattingal
Nabeel Kinattingal
TRTamsheel Fatima Roohi
Tamsheel Fatima Roohi
Stress is a disturbance in homeostasis caused by psychological, physiological, or environmental factors. Prolonged reactions to chronic stress can be detrimental, resulting in various metabolic abnormalities, referred to as metabolic syndrome (MS). There is a reciprocal increased risk between MS and major depressive disorder. Recent studies established an association between inflammation and insulin signaling in type 2 diabetes mellitus with depression. In the present review, we discuss chronic low-grade inflammation, pathways of insulin resistance, and brain glucose metabolism in the context of neuroinflammation and depression. Specific attention is given to psychotropic drugs such as bupropion, mirtazapine, and nefazodone, anti-inflammatory drugs like Celecoxib (COX-2 inhibitor), Etanercept, adalimumab, IL-4Ra antagonist, Anti-IL- 17A antibody (Ixekizumab) and lifestyle modifications including exercise, dietary changes, and sleep hygiene. These therapeutic solutions offer potential in treating depression by targeting metabolic conditions like insulin resistance and inflammatory pathways. The article further explains the significance of a nutrition and antioxidants-rich diet, emphasizing the role of omega-3 fatty acids, vitamin D, zinc, and polyphenols, to improve immunity and activate anti-inflammatory signaling pathways.

1 October 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SESwarne E
Swarne E
MSM.S. Srikanth
M.S. Srikanth
ASAyachit Shreyas
Ayachit Shreyas
SDSneha Desai
Sneha Desai
SMSeema Mehdi
Seema Mehdi
KKKamsagara Linganna Krishna
Kamsagara Linganna Krishna

14 January 2024 in European Journal of Pharmacology
Verified
Journal Article
Closed access
ANAbhishek P.R. Nadiga
Abhishek P.R. Nadiga
SUSuman
Suman
KKKamsagara Linganna Krishna
Kamsagara Linganna Krishna

20 September 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ANAbhishek.P.R. Nadig
Abhishek.P.R. Nadig
BHBader Huwaimel
Bader Huwaimel
AAAhmed Alobaida
Ahmed Alobaida
EKEl-Sayed Khafagy
El-Sayed Khafagy
HAHadil Faris Alotaibi
Hadil Faris Alotaibi
KKKamsagara Linganna Krishna
Kamsagara Linganna Krishna
Parkinson's disease (PD) is a progressive neurodegenerative disorder imposing a severe health and socioeconomic burden worldwide. Existing pharmacological approaches for developing PD are poorly developed and do not represent all the characteristics of disease pathology. Developing cost-effective, reliable Zebrafish (ZF) model will meet this gap. The present study was conceived to develop a reliable PD model in the ZF using manganese chloride (MnCl2). Here, we report that chronic exposure to 2 mM MnCl2 for 21 days produced non-motor and motor PD-like symptoms in adult ZF. Compared with control fish, MnCl2-treated fish showed reduced locomotory activity, indicating a deficit in motor function. In the light-dark box test, MnCl2-treated fish exhibited anxiety and depression-like behavior. MnCl2-treated fish exhibited a less olfactory preference for amino acids, indicating olfactory dysfunction. These behavioral symptoms were associated with decreased dopamine and increased DOPAC levels. Furthermore, oxidative stress-mediated apoptotic pathway, decreased brain derived neurotropic factor (BDNF) and increased pro-inflammatory cytokines levels were observed upon chronic exposure to MnCl2 in the brain of ZF. Thus, MnCl2-induced PD in ZF can be a cost-effective PD model in the drug discovery process. Moreover, this model could be potentially utilized to investigate the molecular pathways underlying the multifaceted pathophysiology which leads to PD using relatively inexpensive species. MnCl2 being heavy metal may have other side effects in addition to neurotoxicity. Our model recapitulates most of the hallmarks of PD, but not all pathological processes are involved. Future studies are required to recapitulate the complete pathophysiology of PD.

Verified
Journal Article
Open access
PDF file
SMSeema Mehdi
Seema Mehdi
KMKishor Manohar
Kishor Manohar
ASAtiqulla Shariff
Atiqulla Shariff
Nabeel KinattingalNabeel Kinattingal
Nabeel Kinattingal
SWShahid Ud Din Wani
Shahid Ud Din Wani
KKKamsagara Linganna Krishna
Kamsagara Linganna Krishna
Depression is a common mood disorder characterized by persistent sadness and loss of interest. Research suggests an association between the inclusion of omega-3 fatty acids in the diet and a reduced risk for depression. The present study evaluated the effectiveness of omega-3 fatty acid supplements in alleviating depressive symptoms in patients with mild to moderate depression. A total of 165 patients suffering from mild to moderated depression were randomized to receive omega-3 fatty acid supplementation, an antidepressant (single agent), or a combination of an antidepressant and omega-3 fatty acid supplementation. The clinical features of depression were assessed using the Hamilton Depression Rating Scale (HDRS) during the follow-up period. A statistically significant improvement in depressive symptoms was observed from baseline to first, second and third follow-ups within each treatment arm as measured by HRDS scores (p = 0.00001). Further, the HDRS scores at the third follow-up were significantly lower in patients on combination therapy of omega-3 fatty acid supplement and antidepressants (arm-3) than the patients on the omega-3 fatty acid supplement alone (arm-1) [Q = 5.89; p = 0.0001] or the patients taking an antidepressant alone (arm 2) [Q = 4.36; p = 0.0068]. The combination of an omega-3 fatty acid supplement and an antidepressant elicited significantly higher improvement in depressive symptoms than the supplement or the antidepressant alone.